Primary surgery followed by systemic @entity902 -based chemotherapy is the cornerstone of management for @entity43 . However, the majority of @entity1 have an @entity1442 (stage III/IV) at the time of diagnosis rendering the optimal primary cytoreduction feasible in only a small percentage of cases. A large @entity5 bulk limits the success of subsequent antiblastic therapy. There are two alternatives to overcome this unfavorable situation: (1) employment of ultra-radical interventions such as peritonectomy procedures, to increase the optimal cytoreduction rate; or (2) neoadjuvant chemotherapy. Whether such strategies would have an influence on the final outcome of @entity1 is an issue to be defined in further prospective randomized studies. For second-line therapies no consensus regarding treatment has emerged. When previous effective drug combinations fail, there is virtually no chance of inducing a significant response with second-line treatment. The combination of secondary @entity91 and intraperitoneal hyperthermic perfusion constitutes a feasible and potential option for this subset of @entity1 based on phase II studies. A randomized trial will be conducted to test the effectiveness of this strategy in @entity1 with @entity900 -resistant disease. The indication for second-line treatment is macroscopic residual or relapse within 6 months after the completion of first line chemotherapy.

Management of peritoneal surface component of XXXX .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity91 :: ('MESH:D003398', 'Disease') :: ['CRS'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
